Maternal Urinary Phthalate Metabolites are Associated with Lipidomic Signatures Among Pregnant Women in Puerto Rico

Pahriya Ashrap¹, Max T. Aung², Deborah J. Watkins¹, Bhramar Mukherjee³, Zaira Rosario-Pabón⁴, Carmen M. Vélez-Vega⁴, Akram Alshawabkeh⁵, José F. Cordero⁶, John D. Meeker^{1*}

¹University of Michigan School of Public Health, Department of Environmental Health Sciences, Ann Arbor, Michigan, United States

²University of California, San Francisco, Department of Obstetrics, Gynecology, and Reproductive Sciences, Program on Reproductive Health and the Environment, San Francisco, California, United States

³University of Michigan School of Public Health, Department of Biostatistics, Ann Arbor, Michigan, United statues

⁴University of Puerto Rico Graduate School of Public Health, UPR Medical Sciences Campus, San Juan, Puerto Rico

⁵ College of Engineering, Northeastern University, Boston, Massachusetts, United statues

⁶ Department of Epidemiology and Biostatistics, University of Georgia, Athens, Georgia, United states

*Corresponding author: John D. Meeker, University of Michigan School of Public Health, Department of Environmental Health Sciences, 1415 Washington Heights, Ann Arbor, Michigan 48109, USA, email: meekerj@umich.edu, telephone: 1.734.764.7184

1 ABSTRACT

Background: Phthalates have been reported to alter circulating lipid concentrations in animals,
and investigation of these associations in humans will provide greater understanding of potential
mechanisms for health outcomes.

7 **Objective:** to explore associations between phthalate metabolite biomarkers and lipidomic profiles 8 among pregnant women (n = 99) in the Puerto Rico PROTECT cohort.

9

Methods: We measured 19 urinary phthalate metabolites during 24-28 weeks of pregnancy. Lipidomic profiles were identified from plasma samples by liquid chromatography-mass spectrometry-based shotgun lipidomics. Relationships between phthalates and lipid profiles were estimated using compound-by-compound comparisons in multiple linear regression and dimension reduction techniques. We derived sums for each lipid class and sub-class (saturated, monounsaturated, polyunsaturated) which were then regressed on phthalates. Associations were adjusted for false discovery.

17

Results: After controlling for multiple comparisons, 33 phthalate-lipid associations were identified (q-value<0.05), and diacylglycerol 40:7 and plasmenyl-phosphatidylcholine 35:1 were the most strongly associated with multiple phthalate metabolites. Metabolites of di-2-ethylhexyl phthalate, bis(2-ethylhexyl) phthalate, dibutyl phthalates, and diisobutyl phthalate were associated with increased ceramides, lysophosphatidylcholines, lysophosphatidylethanolamines, and triacylglycerols, particularly those containing saturated and monounsaturated fatty acid chains.

24

Significance: Characterization of associations between lipidomic markers and phthalates during
 pregnancy will yield mechanistic insight for maternal and child health outcomes.

28 Keywords: Biomarkers; Exposure; Phthalates; Lipidomics; Puerto Rico

29 30

31 Impact Statement: This study leverages emerging technology to evaluate lipidome-wide 32 signatures of phthalate exposure during pregnancy. Circulating lipids are critical for biological 33 processes including inflammation, cell-to-cell communication, and metabolism. Therefore, lipid 34 signatures of phthalate exposure provide insight into potential toxicological mechanisms. 35 Characterization of these mechanisms are relevant for informing the etiology of maternal and 36 children's health outcomes.

- 37 38
- 30 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

47 **INTRODUCTION**

48

Phthalates are a group of chemicals that are found in numerous commercially available products like food packaging, vinyl flooring, pharmaceuticals, and personal care products [1, 2]. According to biomonitoring reports, human exposure to phthalates is ubiquitous for children and adults [3, 4], including pregnant women and their fetuses due to transplacental passage of phthalates [5]. Prenatal and early-life exposure to phthalates has been related to adverse pregnancy events [6-11] and childhood developmental and cardiometabolic outcomes [12-16].

55 One of the proposed mechanisms of action and pathways involved in early life phthalate-56 induced adverse effects is disruption of lipids. Animal studies suggest that phthalates influence 57 circulating lipid levels and lipid signaling [17-20], by interfering with peroxisome-proliferator 58 active receptor gamma (PPARy) [21, 22]. This points to the possibility that a similar mechanism 59 is at play for humans. However, the relationship between prenatal phthalate exposure and lipid 60 metabolism has rarely been investigated among humans. In the limited existing research on 61 humans, the focus has been on the relationship between maternal phthalates and specific lipids such as cholesterol and triglycerides [23-25]. Application of lipidomic profiling (lipidomics) of 62 global cellular lipids in a complex biological sample [26], a branch of metabolomics, may inform 63 64 research on the discovery of new potential biomarkers of effect or patterns of change related to 65 environmental exposures, including phthalates. Only one study to date has examined the 66 association between maternal metabolomics, including lipid metabolites, and environmental 67 phthalates in pregnant women (n = 115) from the Center for the Health Assessment of Mothers 68 and Children of Salinas (CHAMACOS) cohort [27]. The authors found significant relationships 69 between maternal phthalate exposure and plasma free fatty acids, lysolipids, ceramides, and 70 triacylglycerols.

71 Our previous research in the Puerto Rico PROTECT birth cohort found associations 72 between prenatal phthalate urine metabolite levels and increased odds of preterm birth [28, 29]. In 73 the PROTECT cohort, we also assessed the relationship between maternal lipidomic profiles and 74 adverse birth outcomes and observed numerous significant lipid signatures for spontaneous preterm birth [30]. In the current study, we sought to explore the association between maternal 75 76 phthalate metabolite biomarkers and lipidomic profiles among pregnant women (n = 99) in the 77 PROTECT birth cohort. In doing so, we contribute to the characterization of the potential 78 mechanism of action for phthalate exposure. We also highlight the utility of lipidomics as a tool 79 in environmental epidemiology in detecting intermediate endogenous biomarkers of phthalate 80 exposures.

- 81 METHODS
- 82
- 83 Study sample

84 This study sample is an exploratory subset of the Puerto Rico PROTECT cohort. The 85 PROTECT cohort began recruitment in 2010 through funding from the National Institute of 86 Environmental Health Sciences Superfund Research Program. Study participants were recruited 87 in the first or second trimester of pregnancy (median 14 weeks gestation). The research protocol 88 was approved by the Ethics and Research Committees of the University of Puerto Rico and 89 participating clinics, the University of Michigan, Northeastern University, and the University of 90 Georgia. Inclusion criteria for recruitment included: participant age between 18 and 40 years; 91 residence in the Northern Karst aquifer region; disuse of oral contraceptives three months before 92 pregnancy; disuse of in vitro fertilization; and no indication of medical records for major 93 obstetrical complications, including pre-existing diabetes. Prenatal spot urine and blood samples 94 were collected during the third study visit at approximately 26 weeks of gestation. From the

larger cohort of 2070 pregnant women, we randomly sampled 100 women with the goal of
achieving a 1:2 case-control ratio of preterm birth, which included 31 cases and 69 controls. We
created and applied inverse probability weights to account for the sampling approach [31].

98

Urinary phthalate measurements

99 Urine was collected in polypropylene containers, divided into aliquots, and frozen at -80 100 °C until shipment overnight to the Division of Laboratory Sciences at the Centers for Disease 101 Control and Prevention (CDC) for analysis. Urinary concentrations of 15 phthalates, two 102 DEHTP, and two DINCH metabolites were measured using on-line solid phase extraction 103 coupled with isotope dilution-high performance liquid chromatography-electrospray ionization-104 tandem mass spectrometry as previously described [32-34]. Measured phthalate metabolites 105 comprised mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate 106 (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-carboxypentyl) 107 phthalate (MECPP), mono-benzyl phthalate (MBzP), monocarboxyoctyl phthalate (MCOP), 108 mono-isononyl phthalate (MNP), mono-oxoisononyl phthalate (MONP), monocarboxynonyl 109 phthalate (MCNP), mono (3-carboxypropyl) phthalate (MCPP), mono-ethyl phthalate (MEP), 110 mono-n-butyl phthalate (MBP), mono-3-hydroxybutyl phthalate (MHBP), mono-isobutyl 111 phthalate (MiBP) and mono-2-hydroxy-iso-butyl phthalate (MHiBP). Measured DEHTP 112 metabolites comprised mono-2-ethyl-5-carboxypentyl terephthalate (MECPTP) and mono-2-113 ethyl-5-hydroxyhexyl terephthalate (MEHHTP) [35, 36]. Measured DINCH metabolites were 114 cyclohexane-1,2-dicarboxylic acid monohydroxy isononyl ester (MHiNCH) and cyclohexane-115 1,2-dicarboxylic acid monocarboxy isooctyl ester (MCOCH) [33]. The sum of di-2-ethylhexyl 116 phthalate metabolites ($\Sigma DEHP$) was calculated by adding the molar fractions of MEHP, 117 MEHHP, MEOHP, and MECPP. To achieve unit comparability, $\Sigma DEHP$ (nmol/ml) was

multiplied by the molecular weight (MW) of MEHP (278.348 g/mol). The resulting units were ng/ml. Specific gravity (SG) was measured using a handheld digital refractometer (Atago Co., Ltd., Tokyo, Japan) at the University of Puerto Rico Medical Sciences Campus at the time of sample collection. Values below the limit of detection (LOD) were imputed with the metabolitespecific LOD/ $\sqrt{2}$ [37].

123 Lipidome measurement

124 Plasma lipids were extracted from blood plasma samples provided by women at the third 125 study visit using a modified Bligh-Dyer method [38] using liquid-liquid extraction at room 126 temperature after spiking with internal standards. Analysis of lipids was performed on reversed 127 phase high-performance liquid chromatography (HPLC), followed by mass spectrometry (MS) 128 analysis that alternates between MS and data dependent MS2 scans using dynamic exclusion in 129 both positive and negative polarity and yields excellent separation of all classes of lipids. The 130 lipids are quantified using Multiquant and normalized by internal standards. Measurements are 131 semi-quantitative and are based on the relative abundance of peak intensities. Quality controls 132 (QC) are prepared by pooling equal volumes of each sample, in addition to a well characterized 133 plasma pools, and are injected at the beginning and end of each analysis and after every 10 134 sample injections, to provide a measurement of the system's stability and performance as well as 135 reproducibility of the sample preparation method [39].

Lipids were identified using the LipidBlast [40] library (computer-generated tandem mass spectral library of 212,516 spectra covering 119,200 compounds from 26 lipid compound classes), by matching the product ions MS/MS data. The method allowed us to measure 587 lipids belonging to 19 different lipid classes which include acylcarnitine (AcyICN), ceramides

140	(CER), cholesterol esters (CE), diacylglycerols (DG), glucosylceramides(GlcCer), free fatty
141	acids (FFA), fatty acid esters of hydroxy fatty acids (FAHFA), lysophosphatidylcholine
142	(LysoPC), lysophosphatidylethanolamine (LysoPE), phosphatidic acid (PA),
143	phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG),
144	plasmenyl-phosphatidylcholine (PLPC), plasmenyl-phosphatidylethanolamine (PLPE),
145	phosphatidylinositol (PI), phosphatidylserine (PS), sphingomyelin (SM), and triacylglycerol
146	(TG). All individual lipids will be mentioned with the nomenclature as X:Y, where X is the
147	length of the carbon chain and Y, the number of double bonds.
148	Statistical Analysis
149	Inverse probability weighting of over-representation of preterm birth cases was applied to
151	all statistical analyses presented in this analysis in order for our study to resemble the proportions
152	of preterm birth in a general population [31]. 11 phthalate metabolites (MEHP, MEHHP, MEOHP,
153	MECPP, MBzP, MCOP, MCNP, MCPP, MEP, MBP, MiBP) and the sum of DEHP metabolites
154	(SDEHP) were included in the statistical analysis. Four phthalate metabolites (MNP, MONP,
155	MHBP, and MHiBP), two DEHTP metabolites (MECPTP, MEHHTP), two DINCH metabolites
156	(MHiNCH, MCOCH) had >15% data missing, therefore were excluded from the analysis.
157	The group sum of the individual lipids' relative abundance that belong to each lipid class
158	(n=19) were calculated to evaluate lipid classes. Considering lipid classes containing saturated,
159	mono-unsaturated, and polyunsaturated fatty acids (PUFAs) may present different biological
160	patterns, 45 lipid subgroups (saturated, mono-unsaturated, poly-unsaturated) were created by
161	grouping lipids based on a priori knowledge of lipid class and the number of double bonds in each

163 Descriptive statistics for lipids were computed to examine their distributions. Spearman correlation

lipid species. Sum of lipids' relative abundance were also created for the 45 sub-groups.

162

164 coefficients were calculated between lipid class, lipid sub-groups and phthalates to visualize crude165 associations.

166 Multiple statistical strategies were used to assess relationships between lipid profiles and 167 phthalates. The relative abundance of individual lipids, group sums, and sub-groups sums were 168 log-transformed due to their skewed distribution. Subsequently, the log-transformed individual 169 lipids, group sums, and sub-group sums were normalized among individuals (rows) by standard 170 normal variate (SNV) normalization. Covariates were selected based on *a priori* considerations 171 from literature review of factors that would influence both lipid concentrations and phthalate 172 levels. Multiple linear regression models were fitted to evaluate the association between phthalates 173 and the lipidome, adjusting for maternal age, maternal education, fetal sex, pre-pregnancy BMI, 174 and weight gain during pregnancy. 1) Single pollutant models were performed for each log-175 transformed and standardized relative abundance of lipid (n=587) regressing on phthalate 176 metabolites (n=12). False discovery rate (FDR) adjusted p-values (q-values), a commonly used 177 method of adjusting for multiple comparisons in lipidomics studies, were used to account for 178 multiple comparisons. 2) Sums for each lipid class (p=19) and lipid sub-group (p=45) (saturated, 179 monounsaturated, polyunsaturated were then regressed on each phthalate metabolite (n=12). The 180 results are presented as estimated percentage changes of lipids, lipid group sums, or sub-group 181 sums with the corresponding 95% confidence intervals and p values per interquartile range (IQR) 182 change in phthalate metabolite concentration.

183

184 **RESULTS**

185

186 Descriptive statistics

187 Demographic and health characteristics of the women in our study are reported in
188 Supplementary Table 1. The mean age of study participants at the time of enrollment was 26.5

years (standard deviation = 5.7). A majority of participants (77%) had some level of higher education experience. In this sample, 44% of participants reported that they were unemployed, and 75% of participant household incomes were below \$50k. Approximately 37% of participants had pre-pregnancy body mass index of greater than 25 kg/m². Most participants did not report smoking (98%) or drinking (92%) during pregnancy.

194 *Phthalates and Lipidome-wide metabolite associations*

195 **Figure 1** is a Manhattan plot indicating $-\log_{10}(p-value)$ for phthalates in association with 196 individual lipids. The dashed line indicates p value = 0.001. The 33 most significant associations 197 after adjusting for false discovery rate (p value<0.001, q value<0.05) were annotated with the 198 individual lipid in the figure. The Manhattan plot depicts that the lipid metabolites from the DG 199 family were mainly associated with DEHP metabolites, while all of the significant signaling lipids 200 from the CER class were found to be associated with MCNP, MCPP, MBP, and MiBP. Among 201 these top associations, the most prevalent and significant signals were for lipid metabolite DG 40:7 202 in association with all four DEHP metabolites (MEHP, MEHHP, MEOHP, and MECPP), MCPP, 203 and MBP. This was also confirmed on a feature level with a Euler diagram (Supplementary 204 Figure 1) showing the overlap between significant lipid metabolite signals found across different 205 phthalate parent compounds. Among all the lipids with significant signals, DG 40:7 overlapped 206 within most of the ellipses. Another such signal is PLPC 35:1, where MEHHP, MEOHP, MECPP, 207 MBP, and MiBP were significantly associated with this lipid metabolite from the PLPC family. In 208 addition, urinary MECPP and MCPP concentrations were significantly associated with lipid 209 metabolite LysoPE 18:0 from the LysoPE class. MBzP, MCOP, and MEP were not associated with 210 any lipid metabolite in these individual models (Figure 1 & Supplementary Table 2).

211 Saturation subgroup associations with pregnancy phenotypes

212 A list of the individual lipids within each saturation group is reported in **Supplementary** 213 Table 3. Associations between phthalates and the summation of individual lipid metabolites based 214 on the degree of saturation in fatty acid hydrocarbon tails are presented in Figure 2. Significant 215 associations after false discovery rate correction (p value<0.001 & q value<0.05) were annotated 216 for lipid subclass with color indicating association direction, with red representing a positive 217 association and blue indicating a negative association. The effect estimates and 95% confidence 218 intervals of the significant associations are also presented in **Supplementary Table 4**. Nearly all 219 significant associations between phthalates and lipid subgroups were positive. The three oxidative 220 DEHP metabolites, MEHHP, MEOHP, MECPP, as well as the summary measurement $\Sigma DEHP$ 221 were all positively associated with increased saturated CER, saturated and mono-unsaturated 222 LysoPE and PA, and saturated TG. Higher MECPP was additionally associated with mono-223 unsaturated CER as well as saturated and mono-unsaturated LysoPC.

For increased MCPP concentrations, we observed higher saturated and poly-unsaturated CER, saturated and mono-unsaturated LysoPE, and mono-unsaturated PE levels. The only negative association was found between increased MCPP concentrations and lower saturated FFA. The DBP metabolite MBP was associated with higher levels of saturated CER, PE, and TG, as well as mono-unsaturated CER, PA, and PE. The DiBP metabolite MiBP was associated with higher mono-unsaturated FFA and PA, in addition to saturated CER, PC, and TG. MBzP, MCOP, MCNP, and MEP were not significantly associated with any subgroup lipid class.

231 Whole lipid classes associations with pregnancy phenotypes

The heat map in **Figure 3** shows the relationships between phthalate metabolites and lipid classes. Spearman ρ ranged from -0.22 to 0.27. Correlations between MECPP with LysoPC (ρ =0.27) and LysoPE (ρ =0.25) were among the most significant and positive, while the correlation

between MEHP and FFA (ρ =-0.22) was the most negative. Figure 4 shows forest plots of the associations between phthalates and whole lipid classes. Among the lipid classes including CER, LysoPC, LysoPE, and TG, we observed the following positive associations (p value<0.001 & q value<0.05) with Σ DEHP (LysoPE), MECPP (CER, LysoPC, LysoPE), MCPP (CER, LysoPE), and MiBP (TG) when clustering all lipid metabolites into their highest level of organization. **Supplementary Table 5** lists the effect estimates and 95% confidence intervals of these associations.

242 **DISCUSSION**

243

244 Using a comprehensive lipidomics platform including almost six hundred lipid species, we 245 explored the associations between phthalates and three hierarchical levels of lipid organization: (1) 246 individual lipidome-wide metabolites, (2) subgroup clustering based on hydrocarbon chain 247 saturation, and (3) whole lipid classes. We found evidence of associations between phthalates and 248 each level of these organizational hierarchies of lipids. At the lipidome-wide level of individual 249 metabolites, biomarkers of exposure to DEHP, MCPP, and MBP were associated with lipid 250 metabolites from the DG family (DG 40:7) and lipids from the CER class. For lipid saturation 251 subgroups, significant positive associations were observed for DEHP exposure biomarkers and 252 saturated CER, mono-unsaturated CER, saturated LysoPC, mono-unsaturated LysoPC, and 253 saturated TG, whereas MECPP was inversely associated with saturated FFA. When we evaluated 254 the broadest level of whole lipid classes, a variety of phthalates are positively associated with CER, 255 LysoPC, LysoPE, and TG lipid classes. The direction of associations indicated that higher 256 concentrations of phthalates were largely associated with increased levels of all of the most 257 strongly associated lipid classes. There was not substantive evidence of associations for phthalates 258 in relation to whole lipid classes such as PA and PE, even though the analysis on the saturation

subgroup level revealed associations with PA and PE lipids containing saturated and monounsaturated fatty acids.

261 We observed some variation in signatures from lipidome-wide analysis to lipid class 262 analysis, and among distinct DG and PLPC classes. This supports the need to measure the 263 associations between phthalates and lipids at an omics-scale to identify important specific lipid-264 derived biomarkers of maternal phthalate exposure on lipid disruption that would not be identified 265 with less precise analyses of whole aggregate lipid classes. We generated a list of 20 individual 266 lipids across several classes (DG, CER, LysoPE, PLPC, and FFA) that had robust significant 267 associations after false discovery rate correction and may be used to uniquely characterize the 268 lipidomic responses induced by exposure to different phthalate parent compounds 269 Among these lipids, DG 40:7 and PLPC 35:1 were the most (Supplementary Table 1). 270 significantly associated with exposure to multiple phthalates and may have high predictability for 271 phthalate-induced disruption during pregnancy.

272 While there is some variation in signatures from lipidome-wide analysis to lipid class 273 analysis, changes to the individual lipidome (represented by PLPC, LysoPE, CER lipids) related 274 to phthalates (DEHP, DBP, and DiBP metabolites) were also observed in the changes of lipid-275 class and sub-class level analysis. For lipid classes including CER, LysoPC, LysoPE, and TG, we 276 observed positive associations with ΣDEHP (LysoPE), MECPP (CER, LysoPC, LysoPE), MCPP 277 (CER, LysoPE), and MiBP. These increases in lipid classes associated with DEHP metabolite 278 concentrations are consistent with previous reports from animal studies showing that exposure to 279 phthalates, particularly DEHP, influence circulating lipid levels and lipid signaling [17-20, 41]. In 280 contrast, a recent study reported that embryonic exposure to DEHP and DBP in zebrafish 281 significantly reduced the levels of individual lipids from the TG and DG classes [42].

282 Complementary enrichment analysis using proteomic data revealed biological processes 283 associated with DBP (xenobiotic stimulus, lipoprotein metabolism, lipid catabolism, and 284 regulation of FA and TG catabolism) and DEHP (lipase activity regulation, lipid absorption, lipid 285 catabolism and metabolism) [42]. As noted in the introduction, one suggested mechanism is that 286 phthalates, known as PPAR-agonists, are interfering with peroxisome-proliferator active receptor 287 gamma (PPARy) and therefore disrupting lipid metabolism [21, 22]. PPARy is a member of the 288 nuclear receptor superfamily that plays critical physiological roles regulating lipid metabolism [43, 289 44]. It is possible that PPARy may serve as a mediator for maternal phthalate exposure and 290 disruption of lipids. Previous studies have reported that PPARy activation can increase both 291 esterification as well as lipolysis [45, 46], which provided evidence for the increased levels of 292 single chain lipid signals in our analysis, including the FFA, DG, and LysoPC, LysoPE families.

293 For lipid saturation subgroups, significant phthalate-induced lipid increases were 294 exclusively observed for several lipid subgroups with saturated and mono-saturated carbon chains 295 and DEHP metabolites (MEHHP, MEOHP, MECPP), MCPP, DBP metabolite (MBP), and DiBP 296 metabolite (MiBP). The significance of the association was particularly related to the saturation of 297 the lipid classes. All of the lipid groups in the above-mentioned associations contain saturated or 298 mono-unsaturated hydrocarbon chains except for the associations between MCPP and poly-299 unsaturated CER.-s-Evidence from limited human studies have shown that increased levels of 300 saturated and/or mono-unsaturated lipids can have negative effects on pregnancy and poor birth 301 outcomes [47-49]. Therefore, the positive signals we observed between phthalates and saturated 302 and mono-unsaturated lipid classes may be a proxy mechanism or mediator for suspected adverse 303 effects of phthalates on pregnancy outcomes. On the other hand, the beneficial effects of the poly-304 unsaturated fatty acids were widely studied in previous literature [49, 50]. Formal mediation

studies will contribute towards better understanding the potential for poly-unsaturated fatty acidsto diminish the toxic effects of phthalates.

307 Previous research on this population has found that MBP and MiBP, biomarkers for DBP 308 and DiBP exposure, were associated with increased odds of preterm birth, and urinary metabolites 309 measured later in the pregnancy were more strongly associated with preterm birth [7]. Two other 310 studies in Boston [8] and Mexico City [51] have also reported an association between DBP and 311 DiBP metabolites and spontaneous preterm birth in pregnant women. Changes in the lipid classes 312 such as FFA, CE, DG, and PLPE, have been related to alteration of gestational length in recently 313 published work on the same Puerto Rico cohort [30]. Further, levels of multiple individual lipids 314 and lipid classes (FFA, CER, PA, PE, and TG) were associated with phthalate metabolites MBP 315 and MiBP in the present work. While our findings need to be confirmed, these findings support 316 the hypothesis that disruption of lipid levels may be a possible pathway mediating phthalates and 317 adverse pregnancy outcomes.

318 Our study employed a lipidome-wide analysis in relation to maternal phthalate 319 exposure, while previous studies of the relationship between phthalate concentrations and lipids 320 have been limited to animal studies or studies on targeted lipids such as triglyceride, LDL, and 321 HDL. The extensive repertoire of lipid metabolites that were measured within the maternal 322 lipidome is an important extension of previous research, as this provides an unprecedented 323 opportunity to consider the maternal plasma lipidome in the context of maternal-neonate health. 324 Importantly, this study contributes to the evolving evidence on the disrupting role of phthalates, 325 most notably with DEHP metabolites on lipids, and is among the first to present these associations 326 on a lipidomic scale.

327 There are a few limitations of this study. The analysis was limited by a fairly small sample 328 size. While the results of this exploratory analysis are biologically plausible and supported by 329 evidence derived from animal studies showing similar results, confirmation in larger diverse 330 cohorts will be required in the future. Because of the cross-sectional nature of the study, windows 331 of vulnerability during pregnancy were not evaluated. Given that phthalate exposure and lipid 332 profiles change across the duration of pregnancy, it is important for future longitudinal studies to 333 evaluate the temporality of the associations between phthalates and maternal lipidome throughout 334 gestation. Although our analyses were adjusted for important potential confounders, residual 335 confounding due to unmeasured variables (e.g., dietary factors) may still exist that could 336 alternatively explain, at least in part, the observed associations.

337 Conclusions

338 We employed a semi-targeted lipidomics analysis with more than five hundred measured 339 metabolites in maternal plasma samples, which provided an opportunity to examine the 340 relationship between urine phthalate metabolite concentrations with the plasma lipidome. We 341 reported associations of maternal exposure to DEHP, DOP, DBP, and DiBP on omics scale plasma lipids and lipid classes among pregnant women, particularly with those containing saturated and 342 343 monounsaturated fatty acid chains. We identified new potential lipidomic markers of phthalate-344 induced disruption during pregnancy. These results provide new insights into the relationship 345 between maternal phthalate exposure and lipidomic profiles during gestation.

346347

Data availability

Data utilized for this analysis can be obtained by reasonable request by contacting the corresponding author (JDM, meekerj@umich.edu)

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the NIEHS, EPA, or Centers for Disease Control and Prevention (CDC). Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the US Department of Health and Human Services.

Author Contributions

P.A.: Statistical analysis; Investigation; Methodology; Writing, review and editing. M.T.A.: Writing, review and editing. D.J.W.: Conceptualization; Funding acquisition. B.M.: Conceptualization; Supervision; Funding acquisition. Z.R.: Data curation; Project administration. C.M.V.: Data curation; Project administration. A.A.: Conceptualization; Funding acquisition. J.F.C.: Conceptualization; Funding acquisition. J.D.M.: Conceptualization; Funding acquisition; Supervision.

Funding

This study was supported by the Superfund Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (grants P42ES017198 and). Additional support was provided from NIEHS grant numbers P50ES026049, R01ES032203, and P30ES017885 and the Environmental influences on Child Health Outcomes (ECHO) program grant number UH30D023251. Support for Max Aung was provided in part by NIH award P30ES030284.

Acknowledgements

We thank the nurses and research staff who participated in cohort recruitment and follow up, as well as the Federally Qualified Health Centers (FQHC) and clinics in Puerto Rico who facilitated participant recruitment, including Morovis Community Health Center (FQHC), Prymed: Ciales Community Health Center (FQHC), Camuy Health Services, Inc. (FQHC), and the Delta OBGyn (Prenatal Clinic).

Competing Interests

The authors declare that they have no financial or other conflict of interests.

REFERENCES

- 1. Heudorf, U., V. Mersch-Sundermann, and J. Angerer, *Phthalates: toxicology and exposure.* Int J Hyg Environ Health, 2007. **210**(5): p. 623-34.
- Hauser, R. and A.M. Calafat, *Phthalates and human health*. Occup Environ Med, 2005.
 62(11): p. 806-18.
- 3. Council, N.R., *Phthalates and cumulative risk assessment: the tasks ahead*. 2009: National Academies Press.
- 4. Centers for Disease Control and Prevention (CDC), *Fourth National Report on Human Exposure to Environmental Chemicals Updated Tables.* 2019.
- 5. Mose, T., et al., *Transplacental transfer of monomethyl phthalate and mono(2-ethylhexyl) phthalate in a human placenta perfusion system.* Int J Toxicol, 2007. **26**(3): p. 221-9.
- 6. Casas, M., et al., *Exposure to Bisphenol A and Phthalates during Pregnancy and Ultrasound Measures of Fetal Growth in the INMA-Sabadell Cohort*. Environ Health Perspect, 2016. **124**(4): p. 521-8.
- 7. Ferguson, K.K., et al., *Environmental phthalate exposure and preterm birth in the PROTECT birth cohort*. Environ Int, 2019. **132**: p. 105099.
- 8. Ferguson, K.K., T.F. McElrath, and J.D. Meeker, *Environmental phthalate exposure and preterm birth.* JAMA Pediatr, 2014. **168**(1): p. 61-67.
- 9. Swan, S.H., *Environmental phthalate exposure and the odds of preterm birth: an important contribution to environmental reproductive epidemiology.* JAMA Pediatr, 2014. **168**(1): p. 14-5.
- 10. Hu, J.M.Y., et al., Associations of prenatal urinary phthalate exposure with preterm birth: the Maternal-Infant Research on Environmental Chemicals (MIREC) Study. Can J Public Health, 2020. **111**(3): p. 333-341.
- 11. Wolff, M.S., et al., *Prenatal phenol and phthalate exposures and birth outcomes*. Environ Health Perspect, 2008. **116**(8): p. 1092-7.
- 12. Philips, E.M., V.W.V. Jaddoe, and L. Trasande, *Effects of early exposure to phthalates and bisphenols on cardiometabolic outcomes in pregnancy and childhood.* Reprod Toxicol, 2017. **68**: p. 105-118.
- 13. Kim, S.H. and M.J. Park, *Phthalate exposure and childhood obesity*. Ann Pediatr Endocrinol Metab, 2014. **19**(2): p. 69-75.
- 14. Bornehag, C.G., et al., *Association of Prenatal Phthalate Exposure With Language Development in Early Childhood.* JAMA Pediatr, 2018. **172**(12): p. 1169-1176.
- 15. Gascon, M., et al., *Prenatal exposure to phthalates and neuropsychological development during childhood.* Int J Hyg Environ Health, 2015. **218**(6): p. 550-8.
- 16. Engel, S.M., et al., *Prenatal phthalate exposure is associated with childhood behavior and executive functioning*. Environ Health Perspect, 2010. **118**(4): p. 565-71.
- 17. Klöting, N., et al., *Di-(2-ethylhexyl)-phthalate (DEHP) causes impaired adipocyte function and alters serum metabolites.* PLoS one, 2015. **10**(12): p. e0143190.

- 18. Bastos Sales, L., et al., *Analysis of lipid metabolism, immune function, and neurobehavior in adult C57BL/6JxFVB mice after developmental exposure to di (2-ethylhexyl) phthalate.* Frontiers in endocrinology, 2018. **9**: p. 684.
- Cao, H., et al., Bis-(2-ethylhexyl) Phthalate Increases Insulin Expression and Lipid Levels in Drosophila melanogaster. Basic & clinical pharmacology & toxicology, 2016. 119(3): p. 309-316.
- 20. Bell, F.P., *Effects of phthalate esters on lipid metabolism in various tissues, cells and organelles in mammals.* Environmental health perspectives, 1982. **45**: p. 41-50.
- 21. Hayashi, Y., et al., *Hepatic peroxisome proliferator-activated receptor α may have an important role in the toxic effects of di (2-ethylhexyl) phthalate on offspring of mice.* Toxicology, 2011. **289**(1): p. 1-10.
- Shoaito, H., et al., *The Role of Peroxisome Proliferator–Activated Receptor Gamma* (*PPAR* γ) in Mono (2-ethylhexyl) Phthalate (MEHP)-Mediated Cytotrophoblast Differentiation. Environmental health perspectives, 2019. **127**(2): p. 027003.
- 23. Perng, W., et al., *Exposure to phthalates is associated with lipid profile in peripubertal Mexican youth.* Environmental research, 2017. **154**: p. 311-317.
- 24. Allison, K., et al., *Prenatal Maternal Phthalate Exposures and Child Lipid and Adipokine Levels at Age Six: A Study from the PROGRESS Cohort of Mexico City.* Environmental Research, 2020: p. 110341.
- 25. Jia, X., et al., *Prenatal maternal blood triglyceride and fatty acid levels in relation to exposure to di (2-ethylhexyl) phthalate: a cross-sectional study.* Environmental health and preventive medicine, 2015. **20**(3): p. 168-178.
- 26. Han, X. and R.W. Gross, *Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples*. Mass spectrometry reviews, 2005. **24**(3): p. 367-412.
- 27. Zhou, M., et al., *Metabolomic Markers of Phthalate Exposure in Plasma and Urine of Pregnant Women*. Front Public Health, 2018. **6**: p. 298.
- 28. Ferguson, K.K., et al., *Environmental phthalate exposure and preterm birth in the PROTECT birth cohort.* Environment international, 2019. **132**: p. 105099.
- 29. Meeker, J., et al., *Environmental phthalate exposure and preterm birth in the Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) birth cohort.* Environmental Epidemiology, 2019. **3**: p. 119.
- 30. Aung, M., et al., *Maternal Lipidomic Signatures in Relation to Spontaneous Preterm Birth and Large-For-Gestational Age Neonates.* 2021.
- 31. Richardson, D.B., et al., *Analyses of case-control data for additional outcomes*. Epidemiology, 2007. **18**(4): p. 441-5.
- 32. Silva, M.J., et al., *Quantification of 22 phthalate metabolites in human urine*. J Chromatogr B Analyt Technol Biomed Life Sci, 2007. **860**(1): p. 106-12.
- 33. Silva, M.J., et al., *Environmental exposure to the plasticizer 1,2-cyclohexane dicarboxylic acid, diisononyl ester (DINCH) in U.S. adults (2000-2012).* Environ Res, 2013. **126**: p. 159-63.
- 34. Silva, M.J., et al., *Exposure to di-2-ethylhexyl terephthalate in the U.S. general population from the 2015-2016 National Health and Nutrition Examination Survey.* Environ Int, 2019. **123**: p. 141-147.

- 35. Lessmann, F., et al., *Metabolism and urinary excretion kinetics of di(2-ethylhexyl) terephthalate (DEHTP) in three male volunteers after oral dosage.* Arch Toxicol, 2016. **90**(7): p. 1659-67.
- Silva, M.J., et al., *Identification of di-2-ethylhexyl terephthalate (DEHTP) metabolites using human liver microsomes for biomonitoring applications*. Toxicol In Vitro, 2015. 29(4): p. 716-21.
- 37. Hornung, R.W. and L.D. Reed, *Estimation of Average Concentration in the Presence of Nondetectable Values*. Applied Occupational and Environmental Hygiene, 1990. **5**(1).
- 38. Bligh, E.G. and W.J. Dyer, *A rapid method of total lipid extraction and purification*. Canadian journal of biochemistry and physiology, 1959. **37**(8): p. 911-917.
- 39. Gika, H.G., et al., *Evaluation of the repeatability of ultra-performance liquid chromatography–TOF-MS for global metabolic profiling of human urine samples.* Journal of Chromatography B, 2008. **871**(2): p. 299-305.
- 40. Kind, T., et al., *LipidBlast in silico tandem mass spectrometry database for lipid identification*. Nature methods, 2013. **10**(8): p. 755.
- 41. Schmidt, J.S., et al., *Effects of di(2-ethylhexyl) phthalate (DEHP) on female fertility and adipogenesis in C3H/N mice*. Environ Health Perspect, 2012. **120**(8): p. 1123-9.
- 42. Mu, X., et al., *New insights into the mechanism of phthalate-induced developmental effects.* Environ Pollut, 2018. **241**: p. 674-683.
- 43. Schoonjans, K., B. Staels, and J. Auwerx, *The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation*. Biochim Biophys Acta, 1996. **1302**(2): p. 93-109.
- 44. Latruffe, N. and J. Vamecq, *Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism*. Biochimie, 1997. **79**(2-3): p. 81-94.
- 45. Haemmerle, G., et al., *ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1*. Nat Med, 2011. **17**(9): p. 1076-85.
- 46. Zechner, R., et al., *FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling*. Cell Metab, 2012. **15**(3): p. 279-91.
- 47. Bobinski, R. and M. Mikulska, *The ins and outs of maternal-fetal fatty acid metabolism*. Acta Biochim Pol, 2015. **62**(3): p. 499-507.
- 48. Ogundipe, E., et al., *Peri-conception maternal lipid profiles predict pregnancy outcomes*. Prostaglandins Leukot Essent Fatty Acids, 2016. **114**: p. 35-43.
- 49. Khaire, A., et al., *Maternal fats and pregnancy complications: Implications for long-term health.* Prostaglandins Leukot Essent Fatty Acids, 2020. **157**: p. 102098.
- 50. Wang, Y., et al., *Dietary variables and glucose tolerance in pregnancy*. Diabetes Care, 2000. **23**(4): p. 460-4.
- 51. Meeker, J.D., et al., *Urinary phthalate metabolites in relation to preterm birth in Mexico city*. Environ Health Perspect, 2009. **117**(10): p. 1587-92.

Figure Legends:

Figure 1. Manhattan plot showing individual lipids associated with urinary phthalate metabolite concentrations. Models were adjusted for maternal age, maternal education, fetal sex, pre-pregnancy BMI, and weight gain during pregnancy.

													lipic	l classes
													•	FFA
				DG	40:7								•	FAHFA
6		DG 40	J:7	•									•	CE
	•													
	DG 40.7	Cer NS 44:1 DG 40:7 PLPC 35:1												
	Userver (LysoPE 18:0) (LysoPE 18:0)												•	DG
	DO 40.7	·					er NS 34:	1]		Cer ND	S 40:0 PLF	PC 35:1	•	GlcCer
(d)0	DG 40:7)		DG 34					Cer	NS 43:1	FF	A 24·1	•	LysoPC
	DG 34:0	PLPC	35:1	DG 32:0									•	LysoPE
og1	·					DG 36:1	Cer NS 4	2:1				er NDS 40:0	•	PA
-	p_value=	=0. <u>00</u> 4	DG	34:0 DG 4	0:7	- Cer NDS	§ 42:1 - C	Cer NS 41:3		Cer NS 43:	^{2]} (Cer NS 36:2	•	PC
	• •	• •					•	•		•		`,	•	PE
		• • •				•	•	•		•••			•	PLPC
2	3.1			Ž	14	•••	•••				- 1		0	PLPE
	19		200 B		44					֥;	2		•	PG
			- 1				16- <u>2</u> 3	2		· ·			٠	PI
						3		2				<u>.</u>	•	PS
				1									•	SM
0	3 . F		3 8	1 St.	31					1. 1	S	311	•	TG
	DEHP	MEHP	MEHHP	MEOHP	MECPP	MBzP	MCOP	MCNP	MCPP	MEP	MBP	MiBP		

Figure 2. Percent change in lipid subgroup sum z-score associated with urinary phthalate metabolite concentrations. Effect estimates are presented as percent change (%) for IQR increase in exposure biomarker concentration^{ab}. Models were adjusted for maternal age, maternal education, fetal sex, pre-pregnancy BMI, and weight gain during pregnancy.



Figure 3. Correlation matrix between specific gravity corrected concentrations of phthalate metabolites and all lipid classes

	Ũ	8.0	8.0	HHR C	JHR C	3 ⁹ .0	R.C	8 .c	NR C	2 ² .6	2.6	3	2
	Qr.	M	M	M	M	M	h	- M	- Ma	M	M	MIL	
FFA	-0.1	-0.22	-0.11	-0.07	-0.08	0.02	-0.15	-0.2	-0.17	-0.04	0.15	0.15	
FAHFA	-0.02	-0.03	0.01	0.01	-0.07	-0.06	-0.18	-0.1	-0.1	-0.16	-0.01	-0.01	
CE	0.03	0.02	0.03	0.01	0.03	-0.06	0.09	0.06	0.07	0.02	-0.06	-0.1	
AcylCN	0.05	-0.06	0.01	0.04	0.11	-0.05	-0.09	-0.04	-0.03	0.19	0.04	0.16	
CER	0.14	-0.02	0.13	0.13	0.2	-0.04	0.01	-0.06	0.14	-0.01	0.11	0.1	
DG	-0.05	-0.03	-0.07	-0.04	-0.03	-0.09	-0.07	-0.04	-0.08	-0.04	0.02	0.13	
GlcCer	0.14	0.14	0.16	0.14	0.11	0.09	-0.07	0.06	0.11	0.12	0.16	0.1	
LysoPC	0.19	0.04	0.16	0.16	0.27	0	0.12	0.05	0.19	0.17	0.09	0.12	
LysoPE	0.19	0.06	0.16	0.14	0.25	0.01	0.13	0.13	0.21	0.22	0.08	0.14	
PA	0.21	0.16	0.18	0.18	0.22	0.12	0.13	0.12	0.18	0.15	0.16	0.15	
PC	0.08	0.04	0.08	0.07	0.1	0.01	0.08	0.08	0.08	0.05	0.05	0.12	
PE	0.08	-0.01	0.08	0.09	0.12	0.04	0.02	0.11	0.1	0.01	0.18	0.15	-
PLPC	0.01	0.15	0.01	0	0	-0.11	-0.09	0.01	-0.04	0.08	-0.1	-0.06	
PLPE	-0.01	0.07	-0.04	-0.04	0.02	-0.15	0	-0.01	0.07	-0.01	-0.14	-0.08	-
PG	0.09	0.05	0.1	0.08	0.1	-0.1	0.03	0.02	0.06	0.07	0.05	0.12	
PI	0.06	-0.1	0.07	0.05	0.08	-0.04	0.09	0.05	0	-0.04	-0.04	0.11	F
PS	-0.03	-0.15	-0.03	-0.02	0	0.03	0.08	0.01	0.05	-0.01	0.08	0.13	
SM	0.1	0.03	0.11	0.11	0.11	0.02	-0.02	0.03	0.04	0.02	0.12	0.16	
TG	0.15	0.11	0.13	0.14	0.17	-0.01	-0.04	-0.06	0.07	0.07	0.14	0.22	

Figure 4. Percent change in lipid class sum z-score associated with urinary phthalate metabolite concentrations. Effect estimates are presented as percent change (%) for IQR increase in exposure biomarker concentration^{ab}. Models were adjusted for maternal age, maternal education, fetal sex, pre-pregnancy BMI, and weight gain during pregnancy.

